- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 16.07. | Why global 3PL providers are essential to easing supply chain challenges | ||
| 16.07. | Navamedic completes dne pharma acquisition | ||
| 16.07. | Acumen and JCR partner on brain delivery therapy for Alzheimer's | ||
| 15.07. | Sino Biopharma spends $951m to acquire China-based LaNova Medicines | ||
| 15.07. | Otsuka to acquire Cantargia's CAN10 for autoimmune diseases | ||
| 15.07. | Vertex and NHS England agree reimbursement for Alyftrek | ||
| 15.07. | LEO Pharma secures rights to Boehringer's Spevigo for $105m | ||
| 15.07. | Health Canada extends Evkeeza approval for children with HoFH | ||
| 14.07. | WHO endorses Gilead's Yeztugo for HIV prevention | ||
| 14.07. | Scaling smart: how small pharma companies can build resilient supply chains | ||
| 14.07. | Illimis secures funding for GAIA-based Alzheimer's therapeutics | ||
| 14.07. | GSK eyes FDA label expansion for RSV vaccine Arexvy to include younger patients | ||
| 14.07. | Ultragenyx receives complete response letter for UX111 BLA | ||
| 14.07. | FDA to review MSD's doravirine/islatravir NDA for HIV-1 | ||
| 11.07. | FDA issues more than 200 CRLs for transparency | ||
| 11.07. | Real-world evidence as a strategic access lever in rare disease drug development | ||
| 11.07. | The unsustainability of clinical trials and need for transformative change | ||
| 11.07. | IGI and AbbVie sign licence deal for cancer and autoimmune therapy | ||
| 10.07. | Enhancing solubility of targeted protein degraders: Better strategies for bioavailability | ||
| 10.07. | CTO East Coast 2025: Global oncology cell therapy market to hit $25bn by 2031 | ||
| 10.07. | How to remain a top CDMO in ADC-led oncology | ||
| 10.07. | Lupin and Zentiva in licence and supply deal for Certolizumab Pegol | ||
| 10.07. | Merck agrees to acquire Verona Pharma for $10bn | ||
| 09.07. | Trump's 200% tariff threat could send shockwaves through pharma supply chains | ||
| 09.07. | Niagen Bioscience signs exclusive licence deal for PD therapy |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .